Try our Advanced Search for more refined results

Expert Analysis

Clarifying Obligation To Report Drug Patent Agreements

Law360, New York (June 7, 2011, 12:12 PM EDT) -- On May 9, 2011, the Federal Trade Commission's Bureau of Competition notified Sanofi-Aventis U.S. LLC, Watson Pharmaceuticals Inc. and Synthon Holding BV that the companies' failure to inform the FTC and the U.S. Department of Justice about patent agreements concerning Sanofi's insomnia drug, Ambien CR, violated the reporting requirements of the Medicare Prescription Drug, Improvement and Modernization Act of 2003. The notifications came in the form of "advisory letters," which purported to clarify the patent agreement filing requirements under the MMA....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Law Firms

Companies

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!